Abram Scientific, a Menlo Park, California-based medical device developer, announced on October 13, 2026, that it has received a contract worth up to $8.3 million from the Defense Advanced Research Projects Agency to advance CoagCare, its investigational portable blood coagulation testing platform. The funding will support development of a handheld diagnostic intended to assess the clotting characteristics of whole blood in less than 10 minutes, potentially providing information for trauma treatment decisions closer to the point of injury.
The contract forms part of DARPA’s Resuscitation and Prevention of Ischemia-Induced Dysfunction programme, known as RAPIID. The initiative seeks to develop field-deployable alternatives to conventional blood products and the diagnostic systems needed to guide their administration. Abram’s CoagCare platform is being developed to characterize clot formation, clot strength and clot breakdown using a compact meter and a disposable test card.
The new award follows a separate $2 million DARPA contract received in October 2025 to support miniaturization of CoagCare. Abram also completed an $11.75 million Series A financing round in February 2026, led by Swiss plasma therapeutics manufacturer Octapharma. These developments provide additional resources for engineering, clinical development and manufacturing, although the newly announced $8.3 million represents a maximum contract value rather than confirmation that the entire amount has already been paid.
The clinical opportunity is significant because uncontrolled bleeding remains a major cause of preventable death after traumatic injury. Rapid identification of clotting abnormalities can help clinicians determine which blood components or hemostatic treatments may be appropriate. However, CoagCare has not yet received FDA marketing clearance, and its proposed faster testing capability has not been established as providing superior patient outcomes compared with existing laboratory or point-of-care technologies.
What will the $8.3 million DARPA contract fund within Abram Scientific’s CoagCare programme?
Abram intends to use the DARPA award to advance CoagCare toward a deployable diagnostic system suitable for challenging operational environments. The programme includes further technology development, preparation for manufacturing and the creation of a configuration designed for military trauma care. It also supports ongoing efforts to obtain United States regulatory clearance for civilian applications involving blood coagulation assessment.
One objective is to optimize CoagCare for use alongside the experimental blood analog products being developed through DARPA’s RAPIID programme. These products are intended to provide selected functions of conventional blood components while reducing dependence on refrigerated storage and donor-based supply chains. A diagnostic capable of rapidly assessing coagulation could help evaluate whether additional hemostatic support is needed during resuscitation.
The contract also supports establishing manufacturing capabilities for the CoagCare meter and its single-use test card. Abram intends to use a common disposable card across civilian and military configurations, potentially creating manufacturing efficiencies if both versions advance successfully. That strategy may simplify production and quality control, although the company has not disclosed validated manufacturing capacity or unit costs.
The funding ceiling is important when interpreting the contract’s financial significance. An award of up to $8.3 million may include performance-dependent obligations or future contract components, and the announcement does not disclose the amount initially obligated. The full potential value should therefore not be treated as immediate revenue or unrestricted cash.
Abram also has a separate October 2025 DARPA contract valued at $2 million. Although the two awards represent a combined announced maximum of $10.3 million, they relate to distinct funding arrangements and development objectives. The company has not provided a consolidated revenue recognition schedule for the contracts.
How does CoagCare measure blood clot formation and breakdown in under 10 minutes?
CoagCare is designed as a compact point-of-care instrument that works with a disposable diagnostic test card. According to Abram, the platform uses proprietary technology to measure whole-blood viscoelastic properties and density. These measurements are intended to characterize the coagulation process from initial clot formation through subsequent clot breakdown, also known as fibrinolysis.
Viscoelastic coagulation testing evaluates the mechanical behavior of blood as a clot develops. Unlike tests that measure isolated clotting parameters, it can provide information about the combined effects of clotting proteins, platelets and fibrin formation. This broader view can be useful when clinicians need to understand why a patient is bleeding or whether a clotting abnormality requires targeted intervention.
CoagCare’s central technical proposition is the ability to provide a comprehensive assessment in less than 10 minutes using a very small blood sample. Abram describes the required volume as a single drop of whole blood, potentially reducing sample collection and preparation requirements. However, the company has not disclosed a complete comparative analytical validation package establishing equivalent accuracy to existing technologies across every clinically relevant condition.
The device is also being developed to operate in environments where vibration and movement may compromise conventional laboratory equipment. Abram identifies ambulances, medical evacuation helicopters and remote trauma settings as potential applications. Its claimed vibration-insensitive design could be relevant in these situations, but field performance under operational conditions will need to be demonstrated.
Speed alone is not sufficient for clinical adoption. A diagnostic must also produce reproducible results, identify important abnormalities and support treatment decisions using validated interpretation criteria. The clinical value of a ten-minute result will depend on whether it provides reliable information that changes patient management appropriately.
Why is rapid coagulation testing important during major trauma and blood loss?
Severe bleeding can reduce circulating blood volume and compromise the delivery of oxygen to tissues. If blood loss continues, patients may develop shock, organ dysfunction and potentially fatal complications. Trauma teams therefore work to control bleeding while restoring circulation and addressing coagulation abnormalities.
Trauma-induced coagulopathy can involve several mechanisms, including loss or consumption of clotting factors, abnormal platelet function and accelerated fibrinolysis. These disturbances may develop during the initial injury response or evolve as resuscitation proceeds. Rapid assessment can help determine whether the patient requires targeted support beyond replacement of circulating blood volume.
Traditional laboratory investigations commonly include prothrombin time, activated partial thromboplastin time, fibrinogen concentration and platelet count. These tests provide important information, but processing, transport and reporting may introduce delays, especially outside major hospitals. They also measure different aspects of coagulation rather than presenting a complete mechanical profile of clot development.
Viscoelastic technologies can provide a more integrated view of clot formation and breakdown. Clinicians may use the results to support decisions about plasma, platelets, fibrinogen-containing products and other treatments according to institutional protocols. However, the effectiveness of any diagnostic-guided treatment pathway depends on the overall clinical context and the evidence supporting the intervention.
A faster portable platform could be especially valuable when patients are being treated far from a hospital laboratory. The potential benefit would be earlier recognition of clinically important abnormalities and more informed use of available resuscitation products. Whether that translates into reduced mortality or fewer transfusions remains an important question for future CoagCare evaluation.
Can CoagCare offer a meaningful speed advantage over TEG and ROTEM systems?
Established viscoelastic testing technologies include thromboelastography, commonly known as TEG, and rotational thromboelastometry, known as ROTEM. These systems are used in selected trauma, cardiac surgery, liver transplantation and other critical care settings. They provide information about clot initiation, development, strength and breakdown using whole-blood samples.
Abram argues that conventional systems may require 30 to 60 minutes for a complete assessment, while CoagCare is designed to characterize the process in less than 10 minutes. The comparison is potentially important because full measurements of later clotting processes can take considerably longer than the first clinically useful outputs. Nevertheless, the timing must be interpreted according to which parameters are being compared.
Existing TEG and ROTEM platforms can already provide certain actionable results within approximately five to ten minutes, depending on the assay and instrument. Some ROTEM results can be available early enough to guide initial treatment decisions, while complete traces and detailed fibrinolysis assessments may require longer. Therefore, CoagCare’s claim should not be interpreted as demonstrating that all competing technologies require at least 30 minutes before producing any useful information.
A clinically meaningful comparison would need to evaluate the time required to obtain specific actionable measurements under equivalent conditions. It would also need to examine accuracy, precision, repeatability and the ability to identify relevant coagulation abnormalities. A device that produces a faster numerical output may not improve care if its results are insufficiently reliable or lack validated treatment thresholds.
Abram’s 2024 research presentation at the International Society on Thrombosis and Haemostasis congress described preliminary development of a portable platform capable of assessing coagulation and fibrinolysis within the proposed timeframe. This provides a research foundation for the company’s performance claims. However, conference-stage analytical findings are not equivalent to an FDA-cleared intended use or a completed prospective clinical outcomes study.
How does DARPA’s RAPIID programme connect portable diagnostics with artificial blood products?
DARPA established the RAPIID programme to address limitations associated with the storage, transportation and availability of conventional blood products during severe trauma. Donor-derived blood components require controlled handling and have finite shelf lives, making logistics especially difficult in remote military operations. These challenges have encouraged research into synthetic or bioengineered products that might provide selected resuscitative functions without the same cold-chain requirements.
The programme builds on an earlier DARPA initiative known as Fieldable Solutions for Hemorrhage with Bio-Artificial Resuscitation Products, or FSHARP. That work investigated synthetic approaches to functions normally provided by whole blood, including oxygen transport, bleeding control and restoration of circulatory volume. RAPIID is intended to move promising components closer to clinical development, manufacturing scale-up and practical deployment.
DARPA has described RAPIID as a 36-month programme divided into two phases. The initial 12-month phase focuses on preclinical safety and efficacy work and manufacturing readiness, while the subsequent 24 months are intended to advance blood analog products toward early human clinical studies and commercialization planning. The agency has described an ambition to achieve a deployable, FDA-authorized system as early as fiscal year 2029, although this remains a programme objective rather than an assured regulatory outcome.
The initiative includes a technical area focused on the technologies needed to administer and evaluate blood analog products in the field. This is where rapid coagulation diagnostics become relevant. A portable test could potentially help determine whether particular resuscitation components should be administered or whether further treatment is required.
Abram’s contribution is a diagnostic platform, not a synthetic blood product. The company is not claiming that CoagCare can replace red blood cells, plasma or platelets. Its role would be to provide information that may support selection and monitoring of treatments developed by other participants in the wider programme.
Why is Octapharma’s $11.75 million investment strategically important?
Abram completed an $11.75 million Series A financing round in February 2026, led by Octapharma AG, the privately held Swiss manufacturer of plasma-derived and recombinant therapeutics. The round included participation from existing and new investors associated with the University of Colorado Anschutz. The financing provided additional capital for CoagCare development before the latest DARPA award.
Octapharma’s involvement is strategically relevant because the company supplies treatments used in immunology, hematology and critical care. These areas include disorders in which blood coagulation and appropriate use of plasma-derived therapies are important. A reliable portable diagnostic could potentially complement clinical use of coagulation-related products, although the companies have not announced an exclusive commercial distribution arrangement.
The investment also represents an expansion of Octapharma’s innovation activities into diagnostics. Rather than investing solely in new therapeutic products, the company is supporting technology intended to improve how clinicians assess patient needs. This could help connect diagnostic information with individualized treatment decisions, provided the necessary validation is achieved.
For Abram, a specialist healthcare investor may offer more than capital by contributing expertise relevant to clinical applications, product development and market access. Nevertheless, the financing does not establish that CoagCare has met regulatory standards or demonstrated improved patient outcomes. Those milestones remain separate from investment decisions.
The DARPA contract adds a different form of support. While venture financing helps fund the company’s broader development strategy, the government contract is tied to specified programme objectives. The two sources of funding may be complementary, but their financial terms and obligations should not be treated as equivalent.
What regulatory testing must Abram complete before CoagCare can enter civilian trauma care?
Abram has confirmed that CoagCare is not currently cleared by the FDA for marketing in the United States. The company is working toward a 510(k) submission intended to support civilian use in blood coagulation assessment during trauma and surgical care. The announcement does not identify a completed FDA clearance, a confirmed submission date or an anticipated agency decision.
The 510(k) process generally requires a manufacturer to demonstrate substantial equivalence to an appropriate legally marketed device. For a diagnostic system, the evidence may involve analytical performance, reliability, usability, labeling and relevant clinical data depending on the proposed intended use and technological characteristics. The precise requirements will depend on the regulatory classification and claims submitted.
Abram will need to establish how accurately CoagCare measures clot formation, strength and fibrinolysis compared with appropriate reference methods. Testing across different coagulation conditions will be important because trauma patients may have complex abnormalities involving multiple components of the hemostatic system. The device’s performance must also remain consistent across the range of operating environments covered by its intended use.
Portability creates additional verification requirements. A device intended for ambulances or helicopters may encounter temperature changes, vibration, variable lighting and limited access to technical support. Reliable sample handling and quality-control procedures will therefore be essential, especially if the system is operated by personnel outside a conventional laboratory.
The disposable test card will also require validated manufacturing processes, shelf-life information and consistent performance across production lots. If military and civilian configurations use the same consumable, manufacturing control will become particularly important as production scales. The contract supports these activities but does not demonstrate that they have already been completed.
What clinical evidence is needed to establish whether CoagCare improves trauma outcomes?
The first major evidence requirement is analytical validation. Investigators must demonstrate that the proposed measurements are accurate and sufficiently reproducible to support their intended clinical interpretation. This may include comparison with established viscoelastic testing methods across samples representing different coagulation abnormalities.
A subsequent question concerns whether clinicians can use CoagCare results to make appropriate treatment decisions. A rapid test may identify abnormal clotting characteristics, but the clinical response depends on validated decision thresholds and treatment protocols. Studies should therefore examine whether the device’s outputs agree with relevant clinical assessments and support appropriate use of transfusion products.
The highest-value evidence would involve outcomes such as time to targeted intervention, blood product utilization, bleeding control and complications. Demonstrating a mortality benefit would require particularly careful study design because many factors influence survival after major trauma. No such benefit has been established for CoagCare in the October announcement.
Operational research will also be necessary. A handheld instrument may work well in a controlled environment but encounter different challenges during emergency transport or battlefield resuscitation. Human factors, sample collection and training requirements can influence whether the system delivers reliable information within the claimed timeframe.
The company will also need to determine which clinical applications provide the clearest route to adoption. Military trauma care, civilian emergency services and hospital operating rooms have different equipment requirements and reimbursement structures. Successful performance in one setting would not automatically establish suitability for every other intended environment.
What commercial opportunities could portable coagulation testing create beyond battlefield medicine?
Although DARPA’s programme is driven by military medical requirements, Abram is also targeting civilian trauma and surgical care. Potential settings include emergency departments, operating rooms, critical care units, ambulances and facilities where advanced coagulation testing is not readily available. These applications could create a broader market if the platform meets regulatory and clinical performance requirements.
Hospitals and emergency services increasingly consider diagnostic turnaround time as part of operational efficiency. A compact system requiring minimal sample preparation could potentially reduce reliance on transporting specimens to centralized laboratories for certain assessments. However, any economic benefit would depend on device pricing, disposable card costs, quality-control requirements and the effect on clinical workflows.
The use of a shared disposable card across military and civilian configurations may support manufacturing efficiency. Higher production volumes could potentially lower unit costs, although Abram has not disclosed cost estimates or commercial pricing. Manufacturing scale also creates obligations involving supply reliability, quality assurance and inventory management.
The company reports that its underlying technology is protected by 17 granted United States and international patents, with additional applications pending. Intellectual property may support future commercialization, but it does not establish freedom from competition or guarantee regulatory success. Established viscoelastic testing manufacturers already have significant clinical and commercial experience.
Abram is privately held and has not disclosed a revenue forecast, valuation associated with the DARPA contract or product launch date. Its progress is therefore most appropriately assessed through completion of development milestones, regulatory submissions, manufacturing readiness and clinically validated performance.
What will determine whether the DARPA award produces a deployable coagulation diagnostic?
The immediate development priorities include refining the portable CoagCare meter, completing the disposable test card production system and validating performance under conditions relevant to trauma care. Abram will also need to demonstrate that its military configuration can function reliably in remote or austere environments. These milestones are more important than the headline contract amount when assessing the project’s technological maturity.
The relationship with DARPA’s blood analog development programme creates an additional challenge. The diagnostic must provide information relevant to the selection or monitoring of experimental resuscitation products, potentially requiring assessment of blood characteristics that differ from those encountered with conventional transfusion. The company has not disclosed completed validation demonstrating CoagCare’s performance with every proposed analog component.
For civilian use, the decisive regulatory milestone will be an appropriate FDA submission followed by the agency’s determination. Successful clearance would establish the permitted marketing framework for the specified intended use, but not necessarily prove that the device improves survival or lowers transfusion costs. Those claims would require supporting clinical evidence.
Abram’s October 2026 award provides substantial potential government support for a technology addressing a genuine operational problem in emergency medicine. The combination of DARPA funding, Octapharma-led venture capital and a targeted manufacturing strategy positions CoagCare for continued development, but its claimed speed and portability must be matched by dependable analytical performance.
The central question is whether Abram can deliver sufficiently accurate coagulation information within ten minutes under real-world emergency conditions and demonstrate that the results help clinicians make better treatment decisions. Achieving that goal could create opportunities across military and civilian trauma care, but the platform remains investigational. The next meaningful milestones are validated performance data, manufacturing progress and FDA regulatory clearance, rather than the maximum contract value alone.
